Floatz logo

LIDOCAINE

Neuralgia

Ataturk UniversitySmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Neuralgia cohort.

Asset / SponsorPhaseRating
Bxcl501
Universidad Juárez Autónoma de Tabasco
Phase 4BBB
MIDAZOLAM
Minia University
Phase 4BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Medipol University
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Margaux M. Salas, PhD
Phase 4BBB
Capsaicin
University Hospital, Clermont-Ferrand
Phase 4BBB

View all 50 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →